4 completed, 1 terminated, 1 unknown. 6 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 1 | 5 | Completed 3, Terminated 1, Unknown 1 |
Follow mavorixafor: new trials by email Literature Review of mavorixafor trials Research Report on mavorixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders Mavorixafor - Neutropenia | Phase 1 / Phase 2 | Completed | X4 Pharmaceuticals | 32 | 2021-10-16 | 2025-08-06 |
| A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC X4P-001 - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Abbisko Therapeutics Co, Ltd | 24 | 2021-07-21 | 2021-11-02 |
| Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma X4P-001, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | X4 Pharmaceuticals | 9 | 2016-12-07 | 2022-12-29 |
| A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome X4P-001 - WHIM Syndrome | Phase 2 | Completed | X4 Pharmaceuticals | 8 | 2016-12-01 | 2024-10-30 |
| Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma X4P-001, axitinib - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | X4 Pharmaceuticals | 74 | 2016-04-27 | 2024-10-03 |
| Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients AMD11070 - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 6 | 2004-11-01 | 2021-11-09 |
Carcinoma, Renal Cell (2) · Glycogen Storage Disease Id (1) · HIV Infections (1) · Neutropenia (1) · Triple Negative Breast Neoplasms (1) · WHIM syndrome (1)
X4 Pharmaceuticals (4) · Abbisko Therapeutics Co, Ltd (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (5) · Australia (1) · China (1) · South Korea (1)
J L Zheng, Director (1) · Michael S. Saag, MD (1)
2016 (1)